Bank of Hawaii Cuts Stake in Johnson & Johnson (NYSE:JNJ)

Bank of Hawaii lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 7.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 50,658 shares of the company’s stock after selling 3,883 shares during the quarter. Bank of Hawaii’s holdings in Johnson & Johnson were worth $8,210,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of JNJ. China Universal Asset Management Co. Ltd. purchased a new position in Johnson & Johnson in the 1st quarter valued at approximately $765,000. Industrial Alliance Investment Management Inc. boosted its holdings in Johnson & Johnson by 22.7% in the first quarter. Industrial Alliance Investment Management Inc. now owns 8,056 shares of the company’s stock valued at $1,274,000 after purchasing an additional 1,488 shares during the period. Sweeney & Michel LLC acquired a new position in Johnson & Johnson during the 1st quarter worth $5,309,000. Virtus Investment Advisers Inc. increased its holdings in Johnson & Johnson by 377.8% during the 1st quarter. Virtus Investment Advisers Inc. now owns 2,714 shares of the company’s stock worth $429,000 after purchasing an additional 2,146 shares during the period. Finally, Dynasty Wealth Management LLC purchased a new position in shares of Johnson & Johnson in the 1st quarter valued at about $1,213,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction dated Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the transaction, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. This trade represents a 22.90 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Stock Down 0.2 %

Shares of Johnson & Johnson stock opened at $155.17 on Monday. The company has a market cap of $373.59 billion, a P/E ratio of 22.46, a PEG ratio of 2.76 and a beta of 0.53. The firm has a fifty day moving average of $160.21 and a two-hundred day moving average of $156.32. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03. Johnson & Johnson has a one year low of $143.13 and a one year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. During the same quarter last year, the firm earned $2.66 earnings per share. The firm’s revenue was up 5.2% compared to the same quarter last year. On average, analysts forecast that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Shareholders of record on Tuesday, November 26th will be given a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 3.20%. The ex-dividend date of this dividend is Tuesday, November 26th. Johnson & Johnson’s payout ratio is 71.78%.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Morgan Stanley raised their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research report on Wednesday, October 16th. Citigroup lifted their price target on Johnson & Johnson from $180.00 to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, October 16th. Finally, Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the company a “neutral” rating in a report on Wednesday, November 6th. Seven equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.